<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> is a frequent genetic conjugation abnormality associated with adverse drug effects </plain></SENT>
<SENT sid="1" pm="."><plain>Genetic <z:chebi fb="15" ids="17659">UDP</z:chebi> glucuronosyltransferase (UGT)1A gene variants can influence gene transcription, inducibility and glucuronidation activity </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="37670">Protease inhibitors</z:chebi> used in human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> can inhibit UGTs </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="44032">Indinavir</z:chebi> (IDV) can lead to <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> (UGT1A1*28), which does not explain interindividual severity differences and may thus involve additional UGT1A variants </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: One hundred and twenty-five HIV patients receiving IDV and 427 healthy blood donors were genotyped for the presence of UGT1A1*28, UGT1A3 -66T/C, UGT1A7 -57T/G, UGT1A7(N129K/R131K) using Taqman 5' nuclease assays </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0002904'>Hyperbilirubinemia</z:hpo> was observed in 42% </plain></SENT>
<SENT sid="6" pm="."><plain>UGT1A1*28 frequencies did not differ between HIV patients and controls but were significantly higher in hyperbilirubinemic patients </plain></SENT>
<SENT sid="7" pm="."><plain>The frequency of homozygous carriers of the 4 UGT1A marker haplotype increased with <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> affecting <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels &gt;85 micromol/l </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In IDV treatment the risk of severe <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> is associated with genetic variants of the UGT1A3 and UGT1A7 genes in addition to <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> (UGT1A1*28) </plain></SENT>
<SENT sid="9" pm="."><plain>This haplotype is a useful predictor of <z:chebi fb="0" ids="37670">protease inhibitor</z:chebi>-induced side effects </plain></SENT>
</text></document>